Coverage and compliance of mass drug administration against lymphatic filariasis in Kalaburgi district

Mallikarjun K. Biradar; Sharankumar Holyachi

doi:10.18203/2394-6040.ijcmph20172848

Authors

Mallikarjun K. Biradar Department of Community Medicine, Koppal Institute of Medical Sciences, Koppal, Karnataka, India
Sharankumar Holyachi Department of Community Medicine, Koppal Institute of Medical Sciences, Koppal, Karnataka, India

DOI:

https://doi.org/10.18203/2394-6040.ijcmph20172848

Keywords:

Lymphatic filariasis, Mass drug administration, Coverage, Compliance, Diethylcarbamazine, Kalaburgi

Abstract

Background: Lymphatic filariasis (LF) is endemic in 83 countries and territories, with more than a billion people at risk of infection. Filariasis has been a major public health problem in India next only to malaria. Study was done to assess coverage and compliance of mass drug administration (MDA) against lymphatic filariasis in Kalaburgi districts.

Methods: This cross-sectional coverage evaluation survey was done in one urban and three rural clusters in district.

The data was compiled, tabulated and analyzed using proportions.

Results: A total of 791 subjects were interviewed, male subjects constituted about 47.7%. Majority of the subjects were in the age group of 16-60 years (69.9%), while only 3.2% were in <2years. 82.9% persons have received the drugs. Out of the 530 persons who have received the drugs, 86.9% persons have consumed the drugs. Only 59.9% of study subjects consumed tablets in front of health workers. A total of 69 subjects have not consumed tablets, 20.3% said told fear of side reaction, and 20.3% subjects said they don’t have faith in tablet. Only 11 persons suffered from vomiting and nausea.

Conclusions: There is an urgent need for more effective drug delivery strategies and also proper IEC should be done to educate and to improve the coverage and compliance in the districts.

Metrics

Metrics Loading ...

Author Biographies

Mallikarjun K. Biradar, Department of Community Medicine, Koppal Institute of Medical Sciences, Koppal, Karnataka, India

Associate Professor,Department of Community Medicine,KIMS,Koppal-583231,
Karnataka,India

Sharankumar Holyachi, Department of Community Medicine, Koppal Institute of Medical Sciences, Koppal, Karnataka, India

Assistant Professor,Department of Community Medicine,KIMS,Koppal-583231,
Karnataka,India

References

Krentel A, Fischer P, Manoempil P, Supali T, Servais G, Rückert P. Using knowledge, attitudes and practice (KAP) surveys on lymphatic filariasis to prepare a health promotion campaign for mass drug administration in Alor District, Indonesia. Trop Med Int Health. 2006;11:1731-40.

World Health Organization. Life in the 21 st century: A vision for all. The World Health Report 1998. Available at: http://www.who.int/whr/1998/

en/whr98 en.pdf. Accessed on 29 April 2017.

World Health Organization. Regional strategic plan for elimination of Lymphatic Filariasis (2004-2007) 2004; 1-2. Available at: apps.searo.who.int/pdsdocs/

B0207.pdf. Accessed on 30 April 2017.

Das PK, Ramaiah KD, Augustine DJ, Kumar A. Towards elimination of lymphatic filariasis in India. Trends Parasitol. 2001;17:457–60.

Savioli L, Crompton DWT, Ottesen EA, Montresor A, Hayashi S. Intestinal worms beware: development in antihelminthic chemotherapy usage. Parasitol Today. 1997;13:43–4.

Ottesen EA, Ismail MM, Horton J. The role of albendazole in programmes to eliminate lymphatic filariasis. Parasitol Today. 1999;15:382-6.

National Health Policy 2002. New Delhi: Ministry of Health and Family Welfare, Government of India 2002: 1-39.

World Health Organization. Preparing and implementing a national plan to eliminate Lymphatic filariasis in countries where Onchocerciasis is not co-endemic. Available at: http://whqlibdoc.who.int/hq/2000/WHO_CDS_CPE_CEE_2000.15.pdf. Accessed on 25 April 2017.

El Setouhy M, Ramzy RM, Ahmed ES, Kandil AM, Hussain O, Farid HA, et al. A randomized clinical trial comparing single- and multi-dose combination therapy with diethylcarbamazine and albendazole for treatment of bancroftian filariasis. Am J Trop Med Hyg. 2004;70:191-6.

Dogara M, Nock H, Agbede R, Ndams S, Joseph K. Entomological survey of mosquitoes responsible for the transmission of Lymphatic Filariasis in three endemic villages of Kano State, Nigeria. Int J World Health Societal Politics. 2012;7:2:1-6.

Patel PK. Mass drug administration coverage evaluation survey for lymphatic Filariasis in Bagalkot and Gulbarga districts. Indian J Community Med. 2012;37:101-6.

Mukhopadhyay AK, Patnaik SK, Satya Babu P, Rao KNMB. Knowledge on lymphatic filariasis and mass drug administration (MDA) programme in filaria endemic districts of Andhra Pradesh, India. J Vector Borne Dis. 2008;45:73–5.

Babu BV, Kar SK. Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India. Tropical Med Int Health. 2004;9(6):702–9.

Lahariya C, Mishra A. Strengthening of mass drug administration implementation is required to eliminate lymphatic filariasis from India: an evaluation study. J Vector Borne Dis. 2008;45:313–20.